Iovance Biotherapeutics clinical trials we track

Check company identity source

Phase 3 1 trial

Phase 2 8 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate Description: To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the IRC Time frame: 5 years. After: Measure: Objective Response Rate Description: To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators Time frame: 12 months.

Planned enrollment decreased by 76 participants

Before: 100 participants (planned). After: 24 participants (planned).

Primary completion date changed

Before: Dec 2032. After: Dec 2027.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort 1 and 2: Objective Response Rate Description: To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Time frame: Up to 60 months Measure: Cohort 3: Adverse Events Description: To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 4: Adverse Events Description: To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 4: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR). Time frame: Up to 60 months Measure: Cohort 5: Adverse Events Description: To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events. Time frame: Up to 60 months Measure: Cohort 5: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR). Time frame: Up to 60 months. After: Measure: Cohort 1 and 2: Objective Response Rate Description: To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months Measure: Cohort 3: Number of Participants With Adverse Events Description: To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 4: Number of Participants With Adverse Events Description: To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 4: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months Measure: Cohort 5: Number of Participants With Adverse Events Description: To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events. Time frame: Up to 60 months Measure: Cohort 5: Efficacy/Objective Response Rate Description: To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Time frame: Up to 60 months.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort 1 and 2: Objective Response Rate Measure: Cohort 3: Adverse Events Measure: Cohort 4: Efficacy and Adverse Events Measure: Cohort 5: Efficacy and Adverse Events. After: Measure: Cohort 1 and 2: Objective Response Rate Measure: Cohort 3: Adverse Events Measure: Cohort 4: Adverse Events Measure: Cohort 4: Efficacy/Objective Response Rate Measure: Cohort 5: Adverse Events Measure: Cohort 5: Efficacy/Objective Response Rate.

Check registry source

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: To evaluate the feasibility of producing lifileucel using tumor samples obtained before (Cohort 3D) or during (Cohort 3E) frontline platinum doublet chemotherapy and pembrolizumab in patients with Stage IV NSCLC. After: Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: Percentage of patients for whom lifileucel is successfully manufactured and meets release specification.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 245 participants (planned). After: 225 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 9 Aug 2029. After: 20 Feb 2026.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source